Danaher Corporation (DHR)
| Market Cap | 151.17B |
| Revenue (ttm) | 24.27B |
| Net Income (ttm) | 3.50B |
| Shares Out | 706.35M |
| EPS (ttm) | 4.87 |
| PE Ratio | 43.97 |
| Forward PE | 26.45 |
| Dividend | $1.28 (0.60%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | 3,016,687 |
| Open | 215.47 |
| Previous Close | 216.90 |
| Day's Range | 212.71 - 218.56 |
| 52-Week Range | 171.00 - 258.23 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 247.75 (+15.77%) |
| Earnings Date | Oct 21, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for man... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $247.75, which is an increase of 15.77% from the latest price.
News
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Co...
DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher ...
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to ...
These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings
Danaher Corporation (NYSE:DHR) reported better-than-expected third-quarter financial results on Tuesday.
Danaher: Regaining Growth Momentum
Danaher Corporation is regaining growth momentum, with strong Q3 results, positive 2026 guidance, and robust performance in its Biotechnology segment. DHR's management maintains conservative full-year...
Danaher Still A Hold: Good Q3 Results Alone Don't Make A Great Investment
Danaher Corporation reported solid Q3/25 results with 4.4% revenue growth and improved margins, yet valuation concerns persist. Despite management's optimism for high single-digit long-term growth, Da...
Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President, CEO & Director Mat...
Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?
Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion and non-GAAP adjusted EPS of $1.89, significantly outpa...
Danaher beats quarterly estimates on strength in diagnostic tools and tech
Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3...
Danaher Sales and Profit Rise on Bioprocessing Momentum
Danaher recorded higher third-quarter sales and profit on the back of momentum in its bioprocessing business and better-than-expected sales in its respiratory market.
Danaher Reports Third Quarter 2025 Results
WASHINGTON , Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key Third Quarter 2025 Results Net earnings...
Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher ...
Danaher Stock: Monopoly Margins, Discounted Price
Danaher (NYSE:DHR) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
4 Stocks That Aren't Too Hot to Buy Right Now
Evergy, Danaher, Quanta, and Kinetik are all set to deliver big, Citi analysts calculate.
Danaher: Balanced Portfolio With Upside Potential In 2026
Danaher is undervalued, with strong fundamentals, robust free cash flow, and a "Buy" rating targeting $210 (12.7% upside). DHR's bioprocessing segment drives growth, balancing Life Sciences weakness, ...
Danaher Schedules Third Quarter 2025 Earnings Conference Call
WASHINGTON , Sept. 23, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2025 on Tuesday, October 21, 202...
Analysts' Top S&P 500 Stocks to Buy Now
Microsoft, Broadcom and Amazon.com are just three names making Wall Street's list of top-rated stocks this month. Some of the other equities might surprise you.
Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research
Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif. , Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in glob...
Danaher Announces Quarterly Dividend
WASHINGTON , Sept. 9, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common s...
DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Cor...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Danaher Stock Closes Near Day's High After Key Trading Signal
DHR reverses early down move after Alert
Danaher Appoints Jonathan Leiken as General Counsel
WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vic...
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adj...